Large Compounders’ Reporting Requirements Would Move Closer To Manufacturers’ In Senate Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Compounding manufacturers would have to report adverse events and quality problems much like traditional drug and biologic makers as a Senate committee moves toward mark up of legislation.